Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis

Thorax

Volumn 54, Issue 5, 1999, Pages 380-383

  McCaffery, Kevin ^a,b   Olver, Richard E ^a   Franklin, Margaret ^a   Mukhopadhyay, Somnath ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cystic fibrosis; Staphylococcus aureus; Systematic review

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CARBENICILLIN; CEFADROXIL; CEFALEXIN; CEFUROXIME; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLAVULANIC ACID; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DICLOXACILLIN; ERYTHROMYCIN; FLUCLOXACILLIN; FUSIDIC ACID; GENTAMICIN; LINCOMYCIN; MACROLIDE; METICILLIN; NOVOBIOCIN; OXACILLIN; PENICILLIN G; PENICILLIN V; RIFAMPICIN; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG INTERMITTENT THERAPY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG FUNCTION TEST; META ANALYSIS; ORAL DRUG ADMINISTRATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THORAX RADIOGRAPHY;

EID: 0032897291     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.5.380     Document Type: Article

References (20)

1. 1 Loening-Bauke VA, Mischler E, Myers MG. A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis. J Pediatr 1979;95:630-7.
2. 2 Wright GLT, Harper J. Fusidic acid and lincomycin therapy in staphylococcal infections in cystic fibrosis. Lancet 1970; i:9-14.
3. 3 Weaver LT, Green MR, Nicholson K, et al. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child 1994;70:84-9.
4. 4 Taylor RFH, Hodson ME. Antibiotic prescribing practices in the United Kingdom and Eire. Respir Med 1993;87: 535-9.
5. 5 Olver RE. Method and myth in the treatment of cystic fibrosis. In: Eyre J, Boyd R, eds. Paediatric speciality practice for the 1990s. London: Royal College of Physicians of London, 1991: 183-94.
6. 6 Ramsey BW, Boat TF. Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference. J Pediatr 1994;71:177-92.
7. 7 Mukhopadhyay S, Singh M, Cater JI, et al. Nebulised anti-pseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 1996;51:364-8.
8. 8 Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-91.
9. 9 Lefebvre C. The Cochrane Collaboration: the role of the UK Cochrane Centre in identifying the evidence. Health Library Review 1994;11:235-42.
10. 10 Stutman HR, Marks MI. Cephalexin prophylaxis in newly diagnosed patients with cystic fibrosis. Sixth Annual North American Cystic Fibrosis Conference, Washington DC, 1992: 147-8.
11. 11 Beardsmore CS, Thompson JR, Williams A, et al. Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment. Arch Dis Child 1994;71:133-7.
12. 12 Brown J. Efficacy of antimicrobial drugs against staphylococci in cystic fibrosis. Austral Paediatr J 1980;16:207-9.
13. 13 Shapera RM, Matsen JM. Clindamycin therapy of staphylococcal pulmonary infections in patients with cystic fibrosis. J Pediatr 1981;99:647-50.
14. 14 Szaff M, Hoiby N. Antibiotic treatment of staphylococcus aureus infection in cystic fibrosis. Acta Paediatr Scand 1982;71:821-6.
15. 15 Schlesinger E, Muller W, Von der Hardt H, et al. Effect of long-term continuous anti-staphylococcal antibiotic treatment in young children with cystic fibrosis. In: Lawson D, ed. CF: horizons. Chichester: John Wiley, 1984: 280.
16. 16 Kerrebijn KF. Prospective study on the effect of daily and intermittent antibiotic treatment in cystic fibrosis. In: Lawson D, ed. CF: horizons. Chichester: John Wiley, 1984: 273.
17. 17 Harrison CJ, Marks MI, Welch DF, et al. A multicentric comparison of related pharmacologic features of cephalexin and dicloxacillin given for two months to young children with cystic fibrosis. Pediatr Pharmacol 1985;5:7-16.
18. 18 Jensen T, Lang S, Faber M, et al. Clinical experiences with fusidic acid in cystic fibrosis patients. J Antimicrob Chemother 1990;25(Suppl B):45-52.
19. 19 Ballestero S, Villaverde R, Escobar H, et al. Susceptibility to various anti-microbial agents of Staphylococcus aureus isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1992;111:1193-4.
20. 20 Feigelson J, Pecau Y. Action therapeutique de l'acide fusidique dans la mucoviscidose. Pediatre 1993;29/138: 111-3.